245 related articles for article (PubMed ID: 34985762)
21. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review.
Patnaik MM; Parikh SA; Hanson CA; Tefferi A
Br J Haematol; 2014 May; 165(3):273-86. PubMed ID: 24467717
[TBL] [Abstract][Full Text] [Related]
22. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
Hwang SM; Kim SM; Nam Y; Kim J; Kim S; Ahn YO; Park Y; Yoon SS; Shin S; Kwon S; Lee DS
Leuk Res; 2019 Sep; 84():106190. PubMed ID: 31377458
[TBL] [Abstract][Full Text] [Related]
23. Chronic myelomonocytic leukemia diagnosis and management.
Chan O; Renneville A; Padron E
Leukemia; 2021 Jun; 35(6):1552-1562. PubMed ID: 33714974
[TBL] [Abstract][Full Text] [Related]
24. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
Harada Y; Harada H
Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
[TBL] [Abstract][Full Text] [Related]
25. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.
Patnaik MM; Wassie EA; Padron E; Onida F; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Ketterling RP; Komrokji R; Tefferi A; Solary E
Blood Cancer J; 2015 Jan; 5(1):e270. PubMed ID: 25555161
[TBL] [Abstract][Full Text] [Related]
26. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
[TBL] [Abstract][Full Text] [Related]
27. Novel therapeutic targets for chronic myelomonocytic leukemia.
Lasho T; Patnaik MM
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101244. PubMed ID: 33762099
[TBL] [Abstract][Full Text] [Related]
28. Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia.
Cui Y; Tong H; Du X; Li B; Gale RP; Qin T; Liu J; Xu Z; Zhang Y; Huang G; Jin J; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
Exp Hematol Oncol; 2015; 4():14. PubMed ID: 26019984
[TBL] [Abstract][Full Text] [Related]
29. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.
Patnaik MM; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Knudson RA; Ketterling RP; Tefferi A; Solary E
Leukemia; 2014 Nov; 28(11):2206-12. PubMed ID: 24695057
[TBL] [Abstract][Full Text] [Related]
30. [Clinical Characteristics and Survival Analysis of Patients with Chronic Myelomonocytic Leukemia].
Wang JY; Chen JF; Wang SF; Guo QH; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):476-482. PubMed ID: 37096522
[TBL] [Abstract][Full Text] [Related]
31. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.
Patnaik MM; Padron E; LaBorde RR; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Al-kali A; Pardanani A; Ali NA; Komrokji RS; Tefferi A
Leukemia; 2013 Jul; 27(7):1504-10. PubMed ID: 23531518
[TBL] [Abstract][Full Text] [Related]
32. Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
Motohashi K; Fujisawa S; Doki N; Kobayashi T; Mori T; Usuki K; Tanaka M; Fujiwara S; Kako S; Aoyama Y; Onoda M; Yano S; Gotoh M; Kanamori H; Takahashi S; Okamoto S;
Leuk Lymphoma; 2018 Jun; 59(6):1332-1337. PubMed ID: 29032731
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population.
Wedge E; Hansen JW; Dybedal I; Creignou M; Ejerblad E; Lorenz F; Werlenius O; Ungerstedt J; Holm MS; Nilsson L; Kittang AO; Antunovic P; Rohon P; Andersen MK; Papaemmanuil E; Bernard E; Jädersten M; Hellström-Lindberg E; Grønbæk K; Ljungman P; Friis LS
Transplant Cell Ther; 2021 Dec; 27(12):991.e1-991.e9. PubMed ID: 34500124
[TBL] [Abstract][Full Text] [Related]
34. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.
Wassie EA; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Ketterling RP; Solary E; Tefferi A; Patnaik MM
Am J Hematol; 2014 Dec; 89(12):1111-5. PubMed ID: 25195656
[TBL] [Abstract][Full Text] [Related]
35. Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?
Itzykson R; Fenaux P; Solary E
Best Pract Res Clin Haematol; 2013 Dec; 26(4):387-400. PubMed ID: 24507815
[TBL] [Abstract][Full Text] [Related]
36. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
37. Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.
Tremblay D; Rippel N; Feld J; El Jamal SM; Mascarenhas J
Oncologist; 2021 May; 26(5):406-421. PubMed ID: 33792103
[TBL] [Abstract][Full Text] [Related]
38. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
Padron E; Steensma DP
Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
[TBL] [Abstract][Full Text] [Related]
39. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.
Carr RM; Patnaik MM
Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.
Wattel E; Guerci A; Hecquet B; Economopoulos T; Copplestone A; Mahé B; Couteaux ME; Resegotti L; Voglova V; Foussard C; Pegourié B; Michaux JL; Deconinck E; Stoppa AM; Mufti G; Oscier D; Fenaux P
Blood; 1996 Oct; 88(7):2480-7. PubMed ID: 8839839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
